|
|
NCI-H209 [H209]
|
|
|
AF Gazdar, JD Minna
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
aggregates in suspension
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: lung
Disease: carcinoma; small cell lung cancer
Derived from metastatic site: bone marrow
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Yes
|
|
|
pRB + (abnormal, RB1)
|
|
|
Amelogenin: X,Y
CSF1PO: 11
D13S317: 11
D16S539: 9,12
D5S818: 12
D7S820: 9
THO1: 7,9
TPOX: 8
vWA: 18,19
|
|
|
This is a hyperdiploid human cell line., The modal chromosome number is 49, occurring at 28% with a frequency of higher ploidies of 1.3%. Ten to eleven markers were common to all cells including: der(1)t(1;3)(p22;p21), del(6)(q21), t(8q18q), del(12)(q13), der(14)t(14;?)(q32;?)., All had a single copy per cell. About 6 other markers were found, but they occurred only once in all metaphases karyotyped. Neither HSR nor DM were detected., Structurally normal B group chromosomes were not detected. All C group chromosomes were paired. A single copy of both the X and Y was found in all cells.
|
|
|
AK-1, 1
ES-D, 1
G6PD, B
Me-2, 0
PGM1, 1-2
PGM3, 1
|
|
|
male
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: Iscove's modified Dulbecco's medium, 90%; fetal bovine serum, 10% - OR - RPMI 1640 medium, 90%; fetal bovine serum, 10%
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: 2 to 3 times per week
The line should be subcultured by dilution with fresh medium. Alternatively, the clusters may be collected by centrifugation and resuspended in fresh medium.
|
|
|
Culture medium, 95%; DMSO, 5%
|
|
|
normal (or near-normal) cell line established from the same patient:ATCC CRL-5948
|
|
|
1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201
1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370
23320: Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563
32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760
32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024
|
|
